Loading...
XSHE
002365
Market cap437mUSD
Jul 10, Last price  
10.46CNY
1D
3.77%
1Q
-24.75%
Jan 2017
-37.37%
IPO
-28.60%
Name

Qianjiang Yongan Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002365 chart
P/E
137.03
P/S
3.94
EPS
0.08
Div Yield, %
0.99%
Shrs. gr., 5y
0.19%
Rev. gr., 5y
-12.93%
Revenues
783m
-6.63%
447,487,684310,299,295319,729,297417,014,860470,697,829522,718,154658,417,063555,893,651549,399,723932,771,7281,005,407,8311,370,443,0521,172,853,5191,565,409,1811,565,409,1811,462,447,5481,462,447,547972,890,144838,814,941783,167,007
Net income
22m
-63.58%
102,583,75165,052,74846,106,94069,768,15575,356,03423,006,61331,722,31017,612,60662,297,043133,150,746178,584,28989,932,164105,559,800111,416,036111,416,042140,349,121140,349,125-12,312,56061,766,02422,493,429
CFO
139m
+31.57%
31,114,49261,079,336158,468,03336,429,21944,063,52591,229,95270,749,51163,648,21819,263,27170,606,59584,534,206197,318,497314,023,302239,545,250206,662,267101,810,834387,279,801244,257,079105,712,681139,083,418
Dividend
Jul 09, 20250.1 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Qianjiang Yongan Pharmaceutical Co., Ltd. engages in production and sale of taurine in China. It produces ethylene oxide, polycarboxylic acid-based water reducer monomers, water reducers, and health products. The company engages in scientific research and technical service, creatine monohydrate, wholesale and retail trade, leasing and business services, and crop farming. Qianjiang Yongan Pharmaceutical Co., Ltd. was founded in 2001 and is based in Qianjiang, China.
IPO date
Mar 05, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT